Education Re-Engineering Early Phase Cancer Drug Development: Decreasing the Time from Novel Target to Novel.....

1. Re-Engineering Early Phase Cancer DrugDevelopment: Decreasing the Time from Novel Target to Novel TherapeuticJames H. Doroshow, M.D. Deputy Director for Clinical &…